Hirschfield, Gideon M.

International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways

Cordell, H. J., Han, Y., Mells, G. F., Li, Y., Hirschfield, G. M., Greene, C. S., Xie, G., Juran, B. D., Zhu, D., Qian, D. C., et al. (2015) · Nature Communications

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 287

A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis

Hirschfield, G. M., Bowlus, C. L., Mayo, M. J., Kremer, A. E., Vierling, J. M., Kowdley, K. V., Levy, C., Villamil, A., Ladrón de Guevara Cetina, A. L., Janczewska, E., et al. (2024) · New England Journal of Medicine

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 286

British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis

Chapman, M. H., Thorburn, D., Hirschfield, G. M., Webster, G. G. J., Rushbrook, S. M., Alexander, G., Collier, J., Dyson, J. K., Jones, D. E., Patanwala, I., et al. (2019) · Gut

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 284

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

Kowdley, K. V., Luketic, V., Chapman, R., Hirschfield, G. M., Poupon, R., Schramm, C., Vincent, C., Rust, C., Parés, A., Mason, A., et al. (2018) · Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 281

Role of endoscopy in primary sclerosing cholangitis: European society of gastrointestinal endoscopy (ESGE) and European association for the study of the liver (EASL) clinical guideline

Aabakken, L., Karlsen, T., Albert, J., Arvanitakis, M., Chazouilleres, O., Dumonceau, J.-M., Färkkilä, M., Fickert, P., Hirschfield, G., Laghi, A., et al. (2017) · Endoscopy

Liver Diseases and ImmunityGallbladder and Bile Duct Disorders

Cited by 255

Primary biliary cholangitis

Lleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 253

Recent advances in clinical practice: Epidemiology of autoimmune liver diseases

Trivedi, P. J., & Hirschfield, G. M. (2021) · Gut

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 244

Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis

Hirschfield, G. M., Liu, X., Han, Y., Gorlov, I. P., Lu, Y., Xu, C., Lu, Y., Chen, W., Juran, B. D., Coltescu, C., et al. (2010) · Nature Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 215

Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double‐blind, randomised, placebo‐controlled, crossover, phase 2a study

Hegade, V. S., Kendrick, S. F. W., Dobbins, R. L., Miller, S. R., Thompson, D., Richards, D., Storey, J., Dukes, G. E., Corrigan, M., Oude Elferink, R. P. J., et al. (2017) · The Lancet

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 206

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., et al. (2017) · The Lancet Gastroenterology & Hepatology

Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors

Cited by 191

A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA

Schattenberg, J. M., Pares, A., Kowdley, K. V., Heneghan, M. A., Caldwell, S., Pratt, D., Bonder, A., Hirschfield, G. M., Levy, C., Vierling, J., et al. (2021) · Journal of Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 191

Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase

Murillo Perez, C. F., Harms, M. H., Lindor, K. D., van Buuren, H. R., Hirschfield, G. M., Corpechot, C., van der Meer, A. J., Feld, J. J., Gulamhusein, A., Lammers, W. J., et al. (2020) · American Journal of Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 188

Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial

Hirschfield, G. M., Chazouillères, O., Drenth, J. P., Thorburn, D., Harrison, S. A., Landis, C. S., Mayo, M. J., Muir, A. J., Trotter, J. F., Leeming, D. J., et al. (2019) · Journal of Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 187

Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age

Trivedi, P. J., Crothers, H., Mytton, J., Bosch, S., Iqbal, T., Ferguson, J., & Hirschfield, G. M. (2020) · Gastroenterology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 183

Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study

Trauner, M., Nevens, F., Shiffman, M. L., Drenth, J. P. H., Bowlus, C. L., Vargas, V., Andreone, P., Hirschfield, G. M., Pencek, R., Malecha, E. S., et al. (2019) · The Lancet Gastroenterology & Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 180

The gut-adherent microbiota of PSC–IBD is distinct to that of IBD

Quraishi, M. N., Sergeant, M., Kay, G., Iqbal, T., Chan, J., Constantinidou, C., Trivedi, P., Ferguson, J., Adams, D. H., Pallen, M., et al. (2017) · Gut

Gut microbiota and healthLiver Diseases and Immunity

Cited by 179

Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study

Trivedi, P. J., Lammers, W. J., van Buuren, H. R., Parés, A., Floreani, A., Janssen, H. L. A., Invernizzi, P., Battezzati, P. M., Ponsioen, C. Y., Corpechot, C., et al. (2016) · Gut

Liver Diseases and ImmunityHepatocellular Carcinoma Treatment and Prognosis

Cited by 178

Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants

Juran, B. D., Hirschfield, G. M., Invernizzi, P., Atkinson, E. J., Li, Y., Xie, G., Kosoy, R., Ransom, M., Sun, Y., Bianchi, I., et al. (2012) · Human Molecular Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 150

Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis

Andersson, A., Kelly, M., Imajo, K., Nakajima, A., Fallowfield, J. A., Hirschfield, G., Pavlides, M., Sanyal, A. J., Noureddin, M., Banerjee, R., et al. (2022) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentAdvanced MRI Techniques and Applications

Cited by 148

Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes

Cheung, A. C., Lapointe‐Shaw, L., Kowgier, M., Meza‐Cardona, J., Hirschfield, G. M., Janssen, H. L. A., & Feld, J. J. (2016) · Alimentary Pharmacology & Therapeutics

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 139

Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response

Trivedi, P. J., Bruns, T., Cheung, A., Li, K.-K., Kittler, C., Kumagi, T., Shah, H., Corbett, C., Al-Harthy, N., Acarsu, U., et al. (2014) · Journal of Hepatology

Liver Diseases and ImmunityLiver Disease and Transplantation

Cited by 132

PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis

Liu, H., Norman, G. L., Shums, Z., Worman, H. J., Krawitt, E. L., Bizzaro, N., Vergani, D., Bogdanos, D. P., Dalekos, G. N., Milkiewicz, P., et al. (2010) · Journal of Autoimmunity

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 130

Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis

Corpechot, C., Carrat, F., Gaouar, F., Chau, F., Hirschfield, G., Gulamhusein, A., Montano-Loza, A. J., Lytvyak, E., Schramm, C., Pares, A., et al. (2022) · Journal of Hepatology

Liver Diseases and ImmunityLiver Disease Diagnosis and Treatment

Cited by 128

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

Hirschfield, G. M., Shiffman, M. L., Gulamhusein, A., Kowdley, K. V., Vierling, J. M., Levy, C., Kremer, A. E., Zigmond, E., Andreone, P., Gordon, S. C., et al. (2023) · Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 127